Cargando…

Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive and inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocellular injury, inflammation, and fibrosis in various stages. More than 20% of patients with NASH will progress to cirrhosis. Currently, there...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Wei, Xu, Guang, Gao, Yuan, Zhao, Jun, Liu, Tingting, Zhao, Jia, Yang, Huijie, Wei, Ziying, Li, Hui, Xu, An-Long, Bai, Zhaofang, Xiao, Xiaohe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560438/ https://www.ncbi.nlm.nih.gov/pubmed/37805545 http://dx.doi.org/10.1186/s12967-023-04380-4

Ejemplares similares

Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008)

Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats
por: Yang, Bai-Bing, et al.
Publicado: (2018)

Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat
por: Li, Xianwei, et al.
Publicado: (2015)

Correction: Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats
por: Yang, Bai-Bing, et al.
Publicado: (2019)

NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation
por: Wang, Zhilei, et al.
Publicado: (2022)

Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury
por: El Gamal, Heba, et al.
Publicado: (2017)

Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment
por: Liu, Tingting, et al.
Publicado: (2022)

Corrigendum to “Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury”
por: El Gamal, Heba, et al.
Publicado: (2019)

The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity
por: Mu, Wenqing, et al.
Publicado: (2022)

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
por: Iyer, Sangeetha, et al.
Publicado: (2019)

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
por: Zhan, Xiaoyan, et al.
Publicado: (2023)

Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC
por: Zhao, Jia, et al.
Publicado: (2023)

The Aldose Reductase Inhibitor Epalrestat Maintains Blood–Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia
por: Zhang, Tongshuai, et al.
Publicado: (2023)

Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat
por: Hotta, N, et al.
Publicado: (2008)

Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90
por: Xu, Guang, et al.
Publicado: (2021)

Dihydrotanshinone I Specifically Inhibits NLRP3 Inflammasome Activation and Protects Against Septic Shock In Vivo
por: Wei, Ziying, et al.
Publicado: (2021)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Tricyclic antidepressants induce liver inflammation by targeting NLRP3 inflammasome activation
por: Mu, Wenqing, et al.
Publicado: (2023)

Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity
por: Gao, Yuan, et al.
Publicado: (2021)

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy
por: Hotta, N, et al.
Publicado: (2012)

Physiological and Pathological Roles of Aldose Reductase
por: Singh, Mahavir, et al.
Publicado: (2021)

In Search of Differential Inhibitors of Aldose Reductase
por: Balestri, Francesco, et al.
Publicado: (2022)

Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome
por: Wang, Zhilei, et al.
Publicado: (2019)

Structure of aldose reductase from Giardia lamblia
por: Ferrell, M., et al.
Publicado: (2011)

Aldose Reductase, Oxidative Stress, and Diabetic Mellitus
por: Tang, Wai Ho, et al.
Publicado: (2012)

Inhibition of Aldose Reductase by Gentiana lutea Extracts
por: Akileshwari, Chandrasekhar, et al.
Publicado: (2012)

Aldose Reductase Differential Inhibitors in Green Tea
por: Balestri, Francesco, et al.
Publicado: (2020)

Human aldose reductase unfolds through an intermediate
por: Sekhon, Gurprit, et al.
Publicado: (2019)

Molecular docking analysis of flavonoids with aldose reductase
por: Kannayiram, Kasthuri, et al.
Publicado: (2022)

Inhibitory activities of selected Kampo formulations on human aldose reductase
por: Onoda, Toshihisa, et al.
Publicado: (2014)

Icariside Ⅱ, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation
por: Wang, Zhilei, et al.
Publicado: (2020)

Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH
por: Ioannou, George N., et al.
Publicado: (2023)

Aldose Reductase Gene Polymorphisms and Diabetic Retinopathy Susceptibility
por: Abhary, Sotoodeh, et al.
Publicado: (2010)

Stereoselectivity of Aldose Reductase in the Reduction of Glutathionyl-Hydroxynonanal Adduct
por: Balestri, Francesco, et al.
Publicado: (2019)

Tracer metabolomics reveals the role of aldose reductase in glycosylation
por: Radenkovic, Silvia, et al.
Publicado: (2023)

In vitro antidiabetic effects of selected fruits and vegetables against glycosidase and aldose reductase
por: Wu, Tong, et al.
Publicado: (2015)

The role of NLRP3 inflammasome in hepatocellular carcinoma
por: Zhao, Huijie, et al.
Publicado: (2023)

N-Acetylcysteine overcomes epalrestat-mediated increase of toxic 4-hydroxy-2-nonenal and potentiates the anti-arthritic effect of epalrestat in AIA model
por: Wang, Linna, et al.
Publicado: (2023)

Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy
por: Reddy, G. Bhanuprakash, et al.
Publicado: (2008)

Aldose Reductase Inhibition Prevents Metaplasia of Airway Epithelial Cells
por: Yadav, Umesh C. S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_93b2url0adhhs9gmd8dv9gpoih